Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Madrigal Pharmaceuticals (MDGL) has shared an update.
Madrigal Pharmaceuticals, Inc. stockholders recently backed significant changes to the company’s 2015 Amended Stock Plan, including a 750,000 share expansion and a 10-year extension through 2035. Additionally, a new one-year minimum vesting period was introduced for post-2024 awards, aligning with the firm’s clawback policies for incentive recovery. These updates were part of several key decisions made at the 2024 Annual Meeting, where stockholders also re-elected board members and ratified the appointment of PricewaterhouseCoopers LLP as their independent auditor for the upcoming fiscal year.
For a thorough assessment of MDGL stock, go to TipRanks’ Stock Analysis page.